NEW YORK (GenomeWeb News) – Response Genetics today said that its revenues in the third quarter dropped 24 percent year over year as both pharmaceutical client and ResponseDX revenues fell.

The firm's total revenues for the third quarter came in at $4.1 million, down from $5.4 million a year ago. Pharma client revenues decreased 35 percent year over year, the Los Angeles-based molecular diagnostics shop said, adding that ResponseDX revenues were down 16 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.